Related Experiment Videos
Spinal meningioma during hydroxyurea therapy. A paradoxycal case report
F Giordano1, A Savarino, C A Pagni
1Neurosurgery Unit, Department of Neuroscience, University of Turin, Via Cellini 1, I-10126 Turin, Italy.
Summary
A 65-year-old woman experienced spinal cord compression from a spinal meningioma after a decade of hydroxyurea therapy for essential thrombocytemia. This case highlights a potential link between hydroxyurea treatment and meningioma development.
Area of Science:
- Neurology
- Oncology
- Hematology
Background:
- Essential thrombocytemia is a myeloproliferative neoplasm.
- Hydroxyurea is a common treatment for essential thrombocytemia.
- Spinal meningiomas are typically benign tumors of the meninges.
Observation:
- A 65-year-old woman presented with symptoms of spinal cord compression.
- The patient had a 10-year history of essential thrombocytemia treated with hydroxyurea (1000 mg/day).
- A spinal meningioma was diagnosed as the cause of her symptoms.
Findings:
- The development of a symptomatic spinal meningioma occurred after prolonged hydroxyurea therapy.
- This case suggests a potential association between hydroxyurea use and meningioma formation.
- The mechanism linking hydroxyurea to meningioma requires further investigation.
Implications:
- Clinicians should consider the potential risk of meningioma in patients on long-term hydroxyurea therapy.
- Further research is warranted to explore the oncogenic potential of hydroxyurea.
- This finding may influence treatment strategies for essential thrombocytemia.